Research and Markets has announced the addition of the "Opportunity Analyzer: Hodgkin's Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024" drug pipelines to their offering.
Hodgkin's lymphoma (HL), or Hodgkin's disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good.
However, treatment options for those patients who have failed first-line treatment are very few, and a significant unmet medical need remains in those patients. Estimated HL market in the 7MM was valued at $316m in 2014. The HL market will increase approximately four-fold over the forecast period, reaching $1.4 billion by 2024 at a CAGR of 16%.
This growth will be driven by label extensions for Adcetris (brentuximab vedotin), which is poised to enter earlier lines of HL therapy, as well as the approval and uptake of premium-priced products, such as the immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab).
Adcetris to retain and extend its lead as the HL market front-runner, with Opdivo and Keytruda making up a significant amount of the market.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Current Treatment Options
6 Unmet Needs Assessment and Opportunity Analysis
7 R&D Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/h55qmx/opportunityanalyze
View source version on businesswire.com: http://www.businesswire.com/news/home/20161010005791/en/Business Wire
Last updated on: 10/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.